PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women
Recruiting · NCT03144648 · Observational (researchers observe without assigning treatment) · Lead sponsor: International Agency for Research on Cancer
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Breast cancer has become a major public health problem in Latin America, as it is the most common form of cancer among women. Women are more likely to develop breast cancer at younger age, and to be diagnosed at an advanced stage compared to western women. Over the past twenty years, the mortality from breast cancer in Latin America has also been increasing very rapidly, and is currently the leading cause of cancer mortality. Little is known on specific risk factors for premenopausal breast cancer in general, and in Latin America in particular. There is a lack of specific knowledge on tumor molecular and pathological characteristics of breast cancer in Latin America premenopausal women, and this has major consequences on cancer treatment and survival. To improve our understanding on determinants of breast cancer incidence and mortality in young Latin America women and support preventive actions, we implemented an international, population-based multi-center study in Latin America: the PRECAMA study (Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women (PRECAMA): a multicenter population-based case-control study). PRECAMA is coordinated by the International Agency for Research on Cancer (IARC), and is conducted within 4 Latin American countries: Mexico, Costa Rica, Colombia and Chile. Major aims of the project are the following: 1. To develop a multi-centric population-based case-control study on breast cancer in premenopausal women in several countries in Latin America with structured collection of individual, clinical, pathological information and biological specimens, according to strictly controlled protocols 2. To characterize, in these populations, the subtypes of premenopausal breast cancer on the basis of their molecular and pathological phenotypes 3. To improve the identification of specific endogenous/exogenous factors, and disentangle the interplay of these different factors with regard to breast tumor subtypes. 4. Provide advanced training, induce a structuring effect on the breast cancer research community in Latin America and influence the public health agenda regarding the management of breast cancer. The results of our study will be of utmost importance to understand the etiology of breast cancer in Latin America countries, and would provide important information on the role of modifiable exposures for breast cancer prevention.
Who can take part
Inclusion criteria
- woman between 20 and 45 years old
- woman less than 3 years older or younger than the case
- living in the area that the study is taking place during the past 3 years
- woman menstruated at least once in the past 12 months
- woman diagnosed with a primary breast cancer by histopathological examination (only for cases)
Exclusion criteria
- woman receiving tumor treatment, such as radiotherapy, chemotherapy or anti-estrogens (for example, tamoxifen) (except treatment for non-melanoma skin cancers)
- woman taking (or has previously taken) any of the following medications in the past 6 months: tamoxifen, Evista (raloxifene), Fareston (toremifene), Aromasin (exemestane), Femara (letrozole), Arimidez (anastrozole) or Megace (megestrol)
- woman suffering from chronic kidney failure
- woman having a pathology that will hinder adequate communication
- woman who is pregnant or nursing
- woman who has been previously diagnosed with a cancer(except for non-melanoma skin cancers)
- any other reason to exclude
Where it is running
13 locations listed.
- Facultad de Medicina, Universidad del Norte - Barranquilla, Colombia
- Barretos Cancer Hospital - Barretos, Brazil
- Hospital Internacional de Colombia Fundacion Cardiovascular de Colombia - Bucaramanga, Colombia
- SENOSAMA foundation - Bucaramanga, Colombia
- Instituto de Oncología HematoOncologos - Cali, Colombia
- Public Health University of Narino - Pasto, Colombia
- Grupo Infección y Cáncer. Universidad de Antioquia - Medellín, Antioquia, Colombia
- International Hospital of Colombia - Bucaramanga, Bucaramanga, Colombia
- INC - Santiago, Independencia, Chile
- Instituto Nacional de Salud Pública (INSP) - Cuernavaca, Morelos, Mexico
- Hso-Crsco - Santiago, Peñalolén, Chile
- FALP - Santiago, Providencia, Chile
- Agencia Costarricense de Investigaciones Biomédicas (ACIB) - San José, Provincia de San José, Costa Rica